With 300+ key products, giants including Philips, Roche, AstraZeneca and Novartis boost China presence at 8th CIIE

CST Updated Nov 06, 2025 10:21

On November 5, 2025, the 8th China International Import Expo (CIIE) witnessed an impressive display of commitment from global healthcare leaders, with giants including Philips, Roche, AstraZeneca, Novartis, Boston Scientific, and Medtronic collectively presenting over 300 key products and solutions.

This strong presence underscores their long-term dedication to the Chinese market and showcases the groundbreaking innovations shaping the future of healthcare.

1. With Nearly 50 Products and Solutions, Philips Spotlights AI-Driven Future of Health at 8th CIIE

As a global health technology leader attending its eighth CIIE, Philips presented under the theme "Innovation with Purpose, Caring for All," showcasing nearly 50 innovative products and solutions. These included ten China-debut products and over ten AI-enabled solutions. Centered around the "Full Journey of Health Care," the exhibition highlighted Philips' achievements in AI-powered imaging diagnosis, smart interventional navigation, and personal health management, demonstrating its commitment to deeply integrating AI into assisted diagnosis, workflow optimization, and reducing clinical workload.

Philips has established five innovation centers and five manufacturing bases in China, with over 95% of its products now developed and manufactured locally. The company dedicates nearly half of its approximately €1.7 billion annual R&D investment to AI and data science, actively releases the China edition of its Future Health Index 2025 Report, and collaborates with Chinese partners to drive the digital transformation of the healthcare system, reinforcing its strategic position as both the second-largest market and a key innovation hub for Philips.

2. Roche to Debut Pipeline, Accelerating Full-Spectrum Leadership

Roche presented under the theme "Leading Innovation, Protecting Lives," with an immersive display highlighting the deep integration of medical innovation and humanistic care. At this year's CIIE, Roche comprehensively showcased over 40 products from its entire portfolio and diverse innovative solutions. Among them, more than ten pipeline and soon-to-be-launched products in China, covering a full spectrum of disease areas, were unveiled together, marking the largest lineup in history.

Key debut highlights included Gazyva®, the first anti-CD20 monoclonal antibody to show positive results in a Phase III randomized clinical trial for lupus nephritis, and the Port Delivery System, the world's first and only eye implant offering a breakthrough solution in ophthalmology. Additionally, Roche showcased for the first time its end-to-end integrated pharmaceutical value chain in China, along with a panoramic view of its newly invested RMB 2.04 billion biologics manufacturing site. As the first multinational pharmaceutical company to achieve localized production of large-molecule antibody biologics in China, the site is expected to reach key construction milestones by the end of next year.

3. AstraZeneca Deepens Commitment to China with New $136 Million to Expand Production Capacity in Qingdao

AstraZeneca participated with the theme "Advancing with China for a Healthier Future." On the first day of the CIIE, AstraZeneca signed a cooperation agreement with the Qingdao High-tech Industrial Development Zone Management Committee, announcing an additional investment of approximately $136 million to expand the production capacity of its Qingdao supply base, further increasing the output of inhalation aerosols.

The same day, government representatives from AstraZeneca's three primary supply bases in China – Wuxi, Taizhou, and Qingdao – gathered at the booth to witness the significant progress in their low-carbon transition. Currently, the Wuxi base has achieved 100% renewable energy usage, the Taizhou base has reduced carbon emissions by 97.5% compared to the 2015 baseline, and the under-construction Qingdao base is expected to achieve near-zero carbon operations after commissioning. AstraZeneca also exhibited for the first time at this CIIE two innovative oncology drugs approved in China this year: Truqap® (capivasertib) and Datroway® (datopotamab deruxtecan).

4. Novartis Showcases Nearly 20 Key Innovative Products

Novartis presented under the theme "Value and Trust," centrally displaying nearly 20 key innovative products, including multiple Prix Galien Award-winning drugs. The radioligand therapy drug Pluvicto® (lutetium Lu 177 vipivotide tetraxetan), which had previously garnered significant attention at the CIIE, received simultaneous approval for two indications in China just before the expo. The radioactive drug production base invested in by Novartis in Haiyan, Zhejiang in 2023, also successfully completed its main structure in October this year and is expected to be operational by the end of 2026.

Simultaneously, Novartis' kidney disease treatment portfolio made its post-approval debut. This includes Fabhalta® (iptacopan), the world's first oral factor B inhibitor targeting the alternative complement pathway, and Vanrafia® (atrasentan), a highly selective endothelin A receptor antagonist that is the first and only drug of its kind approved for IgA nephropathy in China. Novartis is also actively expanding access to medicines. Since 2017, nearly 40 innovative Novartis drugs have been included in the National Reimbursement Drug List (NRDL), ranking among the top multinational pharmaceutical companies.

5. Boston Scientific Showcases Over 80 Innovative Products, Embodying "Global Innovation + Local Manufacturing"

Under the theme "Advancing Science for Life, Moving Ahead Together," Boston Scientific brought over 80 innovative products covering cardiac, peripheral vascular, oncology, urology, digestive, and neuromodulation areas, with six products making their debut.

These products are tightly aligned with local needs, such as the FARAWAVE NAV PFA Catheter and AdVance XP Male Sling System supporting the "silver economy," the Orbera365 Intragastric Balloon System responding to the "Weight Management Year" initiative, and the Intera 3000 Hepatic Artery Infusion Pump for major oncology treatments. Regarding localization, the Boston Scientific Shanghai Lingang Plant was officially completed and opened in October 2024, marking its first manufacturing base in China. Production of the related IVUS catheters is expected to be localized by 2026. Furthermore, Boston Scientific established its first dedicated AI application exhibition area, showcasing multiple AI innovations like the AVVIGO+ Intravascular Ultrasound (IVUS) Diagnosis System.

6. Medtronic Showcases Over 100 Innovative Products and Solutions

Medtronic participated with the theme "Innovating Healthcare Together," presenting over 100 innovative products and solutions, with both booth area and exhibit numbers reaching a record high. This year, Medtronic focused on the deep integration of AI and healthcare, introducing six debut products.

These included the Asia-Pacific debut of the world's first closed-loop rechargeable spinal cord stimulation system, Inceptiv™, and five China debut exhibits, such as the Affera™ Platform and the CathWorks FFRangio® System. Benefiting from the strong spillover effects of the CIIE, more than 30 of Medtronic's star exhibits have been successfully transformed into clinical practice benefiting Chinese patients. Meanwhile, Medtronic has transitioned from "exhibitor" to "investor." Products manufactured at its Medtronic Kanghui (Changzhou) Technology Park have entered the Japanese market, becoming a model of "Made in China for the world." During this CIIE, Medtronic also announced the launch of its first localized AI solution for TAVR procedures, aiming to build a complete diagnosis and treatment chain covering the entire process.